ImmunoACT and Caring Cross sign TriCAR-T cell therapy development deal
The collaboration is set to address the issue of relapse in patients undergoing treatment with conventional anti-CD19 CAR T-cell therapies through the use of TriCAR-T immunotherapy. As per